Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

2.

Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.

Reed E, Dabholkar M, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F.

Oncol Rep. 2000 Sep-Oct;7(5):1123-8.

PMID:
10948350
3.

Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.

Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E.

Int J Mol Med. 1998 Mar;1(3):617-20.

PMID:
9852275
4.

Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.

Dabholkar MD, Berger MS, Vionnet JA, Overton L, Thompson C, Bostick-Bruton F, Yu JJ, Silber JR, Reed E.

Mol Carcinog. 1996 Sep;17(1):1-7.

PMID:
8876669
5.

Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.

Yu J, Dabholkar M, Bennett W, Welsh J, Mu C, Bostickbruton F, Reed E.

Int J Oncol. 1996 Feb;8(2):313-7.

PMID:
21544361
6.

Cisplatin.

Dabholkar M, Reed E.

Cancer Chemother Biol Response Modif. 1996;16:88-110. Review. No abstract available.

PMID:
8639408
7.
8.

Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.

Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M.

Semin Oncol. 1995 Jun;22(3 Suppl 6):90-6. Review.

PMID:
7541159
9.

Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.

Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ, Reed E.

Cancer Res. 1995 Mar 15;55(6):1261-6.

10.

Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes.

Dabholkar M, Vionnet J, Parker R, Bostickbruton F, Dobbins A, Reed E.

Oncol Rep. 1995 Mar;2(2):209-14.

PMID:
21597714
11.

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E.

J Clin Invest. 1994 Aug;94(2):703-8.

12.

Cisplatin.

Dabholkar M, Christian M, Reed E.

Cancer Chemother Biol Response Modif. 1994;15:87-98. Review. No abstract available.

PMID:
7779608
13.

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM.

Cancer Res. 1993 Aug 15;53(16):3694-9.

14.

Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy.

Parker R, Dimery I, Dabholkar M, Vionnet J, Reed E.

Int J Oncol. 1993 Aug;3(2):331-5.

PMID:
21573369
15.

Cisplatin.

Dabholkar M, Reed E.

Cancer Chemother Biol Response Modif. 1993;14:86-97. Review. No abstract available.

PMID:
8312126
16.

Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E.

J Natl Cancer Inst Monogr. 1993;(15):83-8.

PMID:
7912534
17.

Expression of excision repair genes in non-malignant bone marrow from cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E.

Mutat Res. 1993 Jan;293(2):151-60.

PMID:
7678143
18.

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.

Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM, Reed E.

Environ Health Perspect. 1992 Nov;98:53-9.

19.

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E.

J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7.

PMID:
1433335
20.

Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines.

Dabholkar M, Parker R, Reed E.

Mutat Res. 1992 Jun;274(1):45-56.

PMID:
1375331
21.

Host cell reactivation of cisplatin-damaged plasmid DNA in human non-T leukocyte cell lines.

Dabholkar M, Reed E.

Cancer Lett. 1992 Apr 15;63(2):143-50.

PMID:
1314131
22.

Host-cell reactivation of cisplatin-damaged pRSVcat in a human lymphoid cell line.

Dabholkar M, Eastman A, Reed E.

Carcinogenesis. 1990 Oct;11(10):1761-4.

PMID:
2170046
23.

Studies on natural killer cells in chronic myeloid leukemia patients in remission.

Dabholkar M, Tatake RJ, Advani S, Gangal SG.

Neoplasma. 1990;37(1):47-53.

PMID:
1690865
25.

Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission.

Dabholkar M, Advani S, Tatake R, Gangal S.

Leuk Res. 1986;10(2):203-9.

PMID:
3456474

Supplemental Content

Loading ...
Support Center